ALTASCIENCES
Altasciences is pleased to welcome Dr. Beatrice Setnik, Ph.D. to the role of Chief Scientific Officer, supporting our internal and external clients with her expertise in all areas relating to early drug development.
Beatrice has a Ph.D. in Pharmacology and Neuroscience from the University of Toronto and since 2005 has been involved in clinical trials in Canada and the U.S.A.; with Ventana Clinical Research in Canada, King Pharmaceuticals and Pfizer in North Carolina, and since 2014 with Syneos Health (formerly INC Research). She has extensive experience in the design, conduct, and reporting of trials in a wide range of therapeutic areas, including expertise in the assessment of abuse and dependence potential of CNS-active drugs. In addition, she is an Adjunct Professor in the Department of Pharmacology and Toxicology at the University of Toronto and regularly participates in FDA meetings and workshops.
Beatrice’s wealth of knowledge and experience will ensure high-level scientific guidance and input on study designs, protocols, and medical and scientific feasibility for new inquiries for current and prospective clients.
“We are extremely fortunate to add a candidate of such caliber and talent to our team. We look forward to Dr. Setnik’s contributions which will reinforce Altasciences’ extensive offerings in early phase preclinical and clinical research, ” said Chris Perkin, CEO at Altasciences.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements. Altasciences… helping sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190807005422/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Second Quarter and First Half 2025 Earnings19.9.2025 14:30:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2025 results on Friday, September 26, 2025. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 11:00 a.m. EDT, 4:00 p.m. Morocco and London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2025 results at 12:00 p.m. EDT, 5:00 p.m. Morocco and London time (GMT+1) on Friday, September 26, 2025, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exc
GCCA Concrete in Life Global Photography Competition Launches19.9.2025 14:00:00 CEST | Press release
Tens of thousands of entries expected, focusing on concrete's essential role Overall winner of the free-to-enter competition will receive top prize of $10,000 USD With category prizes of $2,500 USD across each theme This year’s Concrete in Life, a popular global photography competition which celebrates the essential role of concrete across the world, has been officially launched. Now in its 7th year, the competition which receives tens of thousands of entries every year from every corner of the world, highlights the sustainability, versatility, beauty and durable presence of the world’s most used material after water. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919202417/en/ Overall Winner, Concrete in Life 2024/25, Venice Beach Skating by Henrik Hagerup, Venice Beach, Los Angeles, USA Run by the Global Cement and Concrete Association (GCCA), the competition is open to everyone - professionals, amateurs, or anyone with
European Commission (EC) Approves Henlius and Organon’s BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively19.9.2025 12:00:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg/1.7 mL,biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919502394/en/ “The EC approvals of BILDYOS and BILPREVDA mark a pivotal moment in expanding access to essential bone care treatments for millions of Europeans, particularly women, who are disproportionately affected by osteoporosis,” said Nico Van Hoecke, Head, International Commercial at Organon.3,4 “These biosimilars may offer additional treatment options across several therapeutic areas associated with bone loss, including osteoporosis, and reflect Organon’s commitment to advancing women’s health through access to im
Cluster Reply Supports Riverty’s AI-first Strategy for Omnichannel,Human-centric Customer Service19.9.2025 11:15:00 CEST | Press release
Cluster Reply, the Reply company specialised in digital platform solutions leveraging Microsoft technologies, has partnered with fintech company Riverty to accelerate the rollout of a pioneering customer service platform – delivered in record time of just 100 days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250919101836/en/ The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The initiative is part of Riverty’s broader strategy to become a leader in AI-powered financial services. The new solution empowers Riverty to deliver efficient, empathetic customer support across all channels while creating a robust foundation for future AI-driven automation. The platform leverages Microsoft Dynamics 365 Custom
L&T Technology Services Joins the MIT Media Lab to Collaborate on AI-led Innovations19.9.2025 10:30:00 CEST | Press release
With access to world-class research and breakthrough problem-solving opportunities, LTTS will explore next-gen technologies in Mobility, Sustainability and Tech L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a multi-year membership agreement with the MIT Media Lab, one of the world’s most prestigious research institutions. As a consortium Lab Member, LTTS intends to explore next-generation advancements in artificial intelligence (AI), underscoring its commitment to driving transformational innovation in Mobility, Sustainability and Tech. As part of the agreement, LTTS will engage in active discussions and information exchange with the Media Lab’s unique cross-disciplinary ecosystem that brings together researchers, innovators and industry leaders. The collaboration not only emphasizes practical AI innovation but also accelerates technology-driven advancements by linking LTTS’ expertise in AI and engineering w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom